New Drugs for HDL-C Disorders: The Beginning

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 23, 42 Issues, 2016

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

New Drugs for HDL-C Disorders: The Beginning

Current Medicinal Chemistry, 21(25): 2947-2951.

Author(s): MyNgan Duong and Stephen J Nicholls.

Affiliation: South Australian Health and Medical Research Institute. PO Box 11060. Adelaide, SA, 5001, Australia.


For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.


Atherosclerosis, cardiovascular disease, HDL, lipids, risk factors.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 21
Issue Number: 25
First Page: 2947
Last Page: 2951
Page Count: 5
DOI: 10.2174/0929867321666140414104130

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science